The Kang laboratory studies stem-cell regulation within the hematopoietic system. Our current focus is microenvironment and cell-signaling regulation of blood stem cells in three contexts: normal blood development and maintenance; in the process of aging; and in the development of leukemia. Our ultimate goal is to reveal molecular mechanism that is uniquely deregulated during aging and/or transformation, which can be used to identify novel biomarkers of disease and targets for the development of therapeutics.
Areas of Expertise
- Hematopoietic stem cell study
- Leukemia stem cell study
- SUMO modification study
Education & Training
PhD, Shanghai Jiao Tong University, 2009
MD, Shanghai Jiao Tong University, 2002
Awards & Honors
- The American Society of Hematology (ASH) Abstract Achievement Award Recipients and Oral Presentation, 2013
- Member, American Society of Hematology (ASH), 2017-present
- Member, American Heart Association (AHA), 2016-present
- Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, Kang X, Luo M, Zou Y, Huang L J, Amatruda J F, Stone T, Winick N, Scherer P E, Zhang C. Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med. 2016 Dec 12.
- Kang X, Jaehyup Kim, Mi Deng, Samuel John, Heyu Chen, Guojin Wu, Hiep Phan, and Cheng Cheng Zhang. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Cell cycle. 2016 Jan 2; 15(1):25-40.
- Kang X, Zhigang Lu, Changhao Cui, Mi Deng, Yuqi Fan, Baijun Dong, Xin Han, FuchunXie, Jeffrey W. Tyner, John E. Coligan, Robert H. Collins, Xiangshu Xiao, M. James You, Chengcheng Zhang. A novel ITIM receptor-mediated signaling pathway is essential for acute myeloid leukemia development. Nat Cell Biol. 2015 May; 17(5): 665-77